title: Celecoxib-erlotinib combination delays growth and inhibits angiogenesis in EGFR-mutated lung cancer.
abstract: Combination treatment for non-small cell lung cancer (NSCLC) is becoming more popular due to the anticipation that it may be more effective than single drug treatment. In addition, there are efforts to genetically screen patients for specific mutations in light of attempting to administer specific anticancer agents that are most effective. In this study, we evaluate the anticancer and anti-angiogenic effects of low dose celecoxib-erlotinib combination in NSCLC in vitro and in vivo. In NSCLC cells harboring epidermal growth factor receptor (EGFR) mutations, combination celecoxib-erlotinib treatment led to synergistic cell death, but there was minimal efficacy in NSCLC cells with wild-type EGFR. In xenograft models, combination treatment also demonstrated greater inhibition of tumor growth compared to individual treatment. The anti-tumor effect observed was secondary to the targeting of angiogenesis, evidenced by decreased vascular endothelial growth factor A (VEGFA) levels and decreased levels of CD31 and microvessel density. Combination treatment targets angiogenesis through the modulation of of the PI3K/AKT and ERK/Raf1-1 pathway in NSCLC with EGFR exon 19 deletions. These findings may have significant clinical implications in patients with tumors harboring EGFR exon 19 deletions as they may be particularly sensitive to this regimen.
authors: The Third Xiang-Ya Hospital, Central South University Changsha 410013, China.
authors: Yi Xiao
authors: YX
authors: Li
authors: The Third Xiang-Ya Hospital, Central South University Changsha 410013, China.
authors: Jia Le
authors: JL
authors: Wang
authors: The Third Xiang-Ya Hospital, Central South University Changsha 410013, China.
authors: Meng
authors: M
authors: Gao
authors: The Third Xiang-Ya Hospital, Central South University Changsha 410013, China.
authors: Hao
authors: H
authors: Tang
authors: The Third Xiang-Ya Hospital, Central South University Changsha 410013, China.
authors: Rong
authors: R
authors: Gui
authors: The Third Xiang-Ya Hospital, Central South University Changsha 410013, China.
authors: Yun Feng
authors: YF
authors: Fu
keywords: EGFR; NSCLC; angiogenesis; celecoxib; erlotinib